Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

Higher air pollution increases the risk of alopecia areata.

Hair loss lowers quality of life, causing embarrassment, frustration, and sexual rejection.

Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Iron supplements combined with Quilib lotion effectively treat hair loss in people with iron deficiency anemia.

High-throughput LC-MS screening is effective for finding new autotaxin inhibitors for asthma treatment.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

ATP-sensitive potassium channels play a role in chloroquine-induced itch in mice.

Disease-specific tools better assess quality of life in alopecia areata patients.

Hair loss significantly affects emotional and social well-being.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Androgenetic alopecia affects men's emotions more than symptoms or daily function.

Low-Level Light Therapy improves quality of life more for women than men with hair loss.

MNC-QQ cell therapy improved hair growth and quality of life in men with androgenic alopecia without adverse effects.

A new taurine-based liquid can help treat hair loss by improving hair follicle health and promoting regrowth.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Current tools inadequately measure quality of life in children with alopecia areata, needing better instruments.

Hair loss significantly affects emotional and social well-being.